Poractant alfa
- Generic Name
- Poractant alfa
- Brand Names
- Curosurf
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 129069-19-8
- Unique Ingredient Identifier
- KE3U2023NP
- Background
Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic...
- Indication
Poractant alfa is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
- Associated Conditions
- Respiratory Distress Syndrome
- Associated Therapies
- -
Prophylactic Minimally Invasive Surfactant Evaluation
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- NorthShore University HealthSystem
- Target Recruit Count
- 200
- Registration Number
- NCT06007547
- Locations
- 🇺🇸
Northshore University Healthsystem, Evanston, Illinois, United States
Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Dr Christophe LENCLUD
- Target Recruit Count
- 20
- Registration Number
- NCT04384731
- Locations
- 🇫🇷
CH Francois Quesnay, Mantes la Jolie, France
Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 2
- Registration Number
- NCT04181255
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
- Conditions
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
- Target Recruit Count
- 108
- Registration Number
- NCT03521063
- Locations
- 🇲🇽
Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico
Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 30
- Registration Number
- NCT02834624
- Locations
- 🇺🇸
University of Missouri, Women's and Children's Hospital, Columbia, Missouri, United States
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 123
- Registration Number
- NCT02452476
- Locations
- 🇺🇸
Martha Naylor, Greenville, North Carolina, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2013-05-22
- Lead Sponsor
- Dr. Sami Ulus Children's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT01860014
- Locations
- 🇹🇷
Zekai Tahir Burak Hospital, Ankara, Turkey
Perfusion Index Variability in Respiratory Distress Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Dr. Sami Ulus Children's Hospital
- Target Recruit Count
- 92
- Registration Number
- NCT01852461
Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia
- Conditions
- Interventions
- First Posted Date
- 2009-12-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Jean Michel Hascoet
- Target Recruit Count
- 118
- Registration Number
- NCT01039285
- Locations
- 🇫🇷
AP-HP Hopital Port Royal, Paris, France
🇫🇷CHU hopital d'enfants, Dijon, France
🇫🇷CHU Hopital Nord, Amiens, France
Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 213
- Registration Number
- NCT00751959
- Locations
- 🇩🇪
Klinikum Stuttgart, Olgahospital, Stuttgart, Germany
🇩🇪DRK Kinderklinik, Siegen, Germany
🇩🇪Ruhr University of Bochum, Children's Hospital St. Josef Spital, Bochum, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.